Cargando…
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events
OBJECTIVE: Women with multiple sclerosis are often diagnosed and treated during their reproductive years. Limited data are available on the safety of treatment during pregnancy. The Betaseron Pregnancy Registry prospectively monitored women exposed to interferon β-1b (IFNβ-1b) during pregnancy to es...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025462/ https://www.ncbi.nlm.nih.gov/pubmed/24821713 http://dx.doi.org/10.1136/bmjopen-2013-004536 |
_version_ | 1782316764605972480 |
---|---|
author | Coyle, P K Sinclair, S M Scheuerle, A E Thorp, J M Albano, J D Rametta, M J |
author_facet | Coyle, P K Sinclair, S M Scheuerle, A E Thorp, J M Albano, J D Rametta, M J |
author_sort | Coyle, P K |
collection | PubMed |
description | OBJECTIVE: Women with multiple sclerosis are often diagnosed and treated during their reproductive years. Limited data are available on the safety of treatment during pregnancy. The Betaseron Pregnancy Registry prospectively monitored women exposed to interferon β-1b (IFNβ-1b) during pregnancy to estimate the rates of birth defects, spontaneous abortions (SABs) and other negative outcomes in this population. DESIGN: From 2006 to 2011, this observational registry enrolled women exposed prior to conception or during pregnancy (but prior to or without abnormalities on prenatal screening). Follow-up continued from enrolment through the 4-month paediatric visit. SETTING: Patients in the USA who met these criteria were enrolled in the registry. RESULTS: The registry enrolled 99 pregnant women; 3 were lost to follow-up. The earliest exposure to IFNβ-1b occurred during the first trimester for 95 pregnancies and in the third trimester for 1 pregnancy. There were 99 birth outcomes (3 twins), including 86 (86.9%) live births, 11 (11.1%) SABs and 2 (2%) stillbirths. Birth defects were reported in five (5.1%) cases. Rates of birth defects and SAB were not significantly different from population comparators. No developmental concerns were identified at the 4-month paediatric visit. CONCLUSIONS: The small sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with IFNβ-1b. CLINICAL TRIALS REGISTRATION NUMBER: NCT00317564. |
format | Online Article Text |
id | pubmed-4025462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-40254622014-05-21 Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events Coyle, P K Sinclair, S M Scheuerle, A E Thorp, J M Albano, J D Rametta, M J BMJ Open Neurology OBJECTIVE: Women with multiple sclerosis are often diagnosed and treated during their reproductive years. Limited data are available on the safety of treatment during pregnancy. The Betaseron Pregnancy Registry prospectively monitored women exposed to interferon β-1b (IFNβ-1b) during pregnancy to estimate the rates of birth defects, spontaneous abortions (SABs) and other negative outcomes in this population. DESIGN: From 2006 to 2011, this observational registry enrolled women exposed prior to conception or during pregnancy (but prior to or without abnormalities on prenatal screening). Follow-up continued from enrolment through the 4-month paediatric visit. SETTING: Patients in the USA who met these criteria were enrolled in the registry. RESULTS: The registry enrolled 99 pregnant women; 3 were lost to follow-up. The earliest exposure to IFNβ-1b occurred during the first trimester for 95 pregnancies and in the third trimester for 1 pregnancy. There were 99 birth outcomes (3 twins), including 86 (86.9%) live births, 11 (11.1%) SABs and 2 (2%) stillbirths. Birth defects were reported in five (5.1%) cases. Rates of birth defects and SAB were not significantly different from population comparators. No developmental concerns were identified at the 4-month paediatric visit. CONCLUSIONS: The small sample size limits the ability to draw definitive conclusions; however, there was no pattern to suggest increased negative outcomes with IFNβ-1b. CLINICAL TRIALS REGISTRATION NUMBER: NCT00317564. BMJ Publishing Group 2014-05-10 /pmc/articles/PMC4025462/ /pubmed/24821713 http://dx.doi.org/10.1136/bmjopen-2013-004536 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Neurology Coyle, P K Sinclair, S M Scheuerle, A E Thorp, J M Albano, J D Rametta, M J Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events |
title | Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events |
title_full | Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events |
title_fullStr | Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events |
title_full_unstemmed | Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events |
title_short | Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events |
title_sort | final results from the betaseron (interferon β-1b) pregnancy registry: a prospective observational study of birth defects and pregnancy-related adverse events |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025462/ https://www.ncbi.nlm.nih.gov/pubmed/24821713 http://dx.doi.org/10.1136/bmjopen-2013-004536 |
work_keys_str_mv | AT coylepk finalresultsfromthebetaseroninterferonb1bpregnancyregistryaprospectiveobservationalstudyofbirthdefectsandpregnancyrelatedadverseevents AT sinclairsm finalresultsfromthebetaseroninterferonb1bpregnancyregistryaprospectiveobservationalstudyofbirthdefectsandpregnancyrelatedadverseevents AT scheuerleae finalresultsfromthebetaseroninterferonb1bpregnancyregistryaprospectiveobservationalstudyofbirthdefectsandpregnancyrelatedadverseevents AT thorpjm finalresultsfromthebetaseroninterferonb1bpregnancyregistryaprospectiveobservationalstudyofbirthdefectsandpregnancyrelatedadverseevents AT albanojd finalresultsfromthebetaseroninterferonb1bpregnancyregistryaprospectiveobservationalstudyofbirthdefectsandpregnancyrelatedadverseevents AT ramettamj finalresultsfromthebetaseroninterferonb1bpregnancyregistryaprospectiveobservationalstudyofbirthdefectsandpregnancyrelatedadverseevents |